This is what intrigues me, if PPO's can't streamline sales, it just happened to happen straight after the agreement was made when they achieved their first commericial sales in the states...
Printable View
sorry I had a typo earlier. I meant that they can streamline sales and that's all they do.
Most commonly biotech startup companies have zero sales for up to five years or more during a research & development / early commercialisation phase.
Those who may attempt to apply p/s ratio’s during this phase clearly have little understanding as to how to value a company like PEB at this stage in its life.
Though I wish them well, they may be missing out on what’s a robust investment in PEB.
http://www.deloitte.com/view/en_CA/c...42f00aRCRD.htm
To mac, do you think the first sales were set off by the provider agreement?
http://www.youtube.com/watch?v=
Interesting DD mentions pacific edge already have their first customer who has ran approx 80 tests back in 31st jan 2013.
Must be Dr. Joe DiTrollo
I don't see why they should not have been Baller, the announcement of first commercial sales was very shortly after the FedMED sign up.
It's important to note also that although PEB haven’t been formally announced as such as a Medicare provider, the PEB website does offer this recent and rather interesting statement;
"Pacific Edge is a Medicare provider. Pacific Edge will accept patients with Medicare coverage, and these patients will have no financial responsibility for Cxbladder."
http://www.cxbladder.com/for-patients/billing-policy/
regards, Mac
Wouldn’t get to excited, by recent I mean over the last six months or so.
From the website it would seem that PEB are though presently accepting patients with Medicare coverage, but we also know that negotiations are ongoing between Pacific Edge and Medicare. This from the ODT, 28th December 2013.
“However, the next crucial step is Pacific Edge gaining clearance from the Centre for Medicaid and Medicare Services (CMS), which oversees and reimburses payments for the US public health system.
Swann welcomed Obama-care, but the legislative changes mean Pacific Edge has to wait longer and make changes to gain CMS accreditation, though he is hopeful it will be through early next year.”
http://www.nzherald.co.nz/business/n...ectid=11178639
If anyone is able to interpret those words ‘clearance’ and ‘accreditation’ then we may all be more enlightened.
It provides a nice paradox, how can billing occur without negotiations being final, perhaps there is some form of interim or transitory agreement in place ?
So if peb did not get coverage it would mean free tests? Logic is a bit flaw there
Coming back to Chris Swanns advice.
As we know the whole sector including CMS had a big shake up last year and it does take bureaucrats a good lengthy period to interpret and prepare policy following new mandates like the Obama-care legislation.
“Swann welcomed Obama-care, but the legislative changes mean Pacific Edge has to wait longer and make changes to gain CMS accreditation, though he is hopeful it will be through early next year.”
http://www.nzherald.co.nz/business/n...ectid=11178639
Fortunately for Pacific Edge most of that disruption seems to come and gone in early to mid 2013, and although PEB are probably still hurdle jumping even now we should be encouraged that accreditation is apparently close.
Once accredited it seems that the Obama-care legislation should greatly benefit companies like PEB. This assessment by Forbes provides some insight;
http://www.forbes.com/sites/genemarc...medical-tests/
It’s a five year plan, patiently onward and forward.